Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Gilead Sciences, Inc.
ISIN US3755581036
|WKN 885823
Market cap (in EUR)
145,134 m
Country
United States
Sector
Healthcare
Dividend yield
2.26%
Overview
Quote
Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Chart
Financials
Key metrics
| Market capitalisation, EUR | 145,134 m |
| EPS, EUR | 5.85 |
| P/B ratio | 8.1 |
| P/E ratio | 21.6 |
| Dividend yield | 2.26% |
Winst- en verliesrekening (2024)
| Revenue, EUR | 26,557 m |
| Net income, EUR | 444 m |
| Profit margin | 1.67% |
In welke ETF zit Gilead Sciences, Inc.?
Er zijn 71 ETF's die Gilead Sciences, Inc. bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van Gilead Sciences, Inc. is de iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Performance
Returns overview
| YTD | +9.87% |
| 1 month | +9.77% |
| 3 months | +14.05% |
| 6 months | +17.70% |
| 1 year | +26.88% |
| 3 years | +51.03% |
| 5 years | +116.08% |
| Since inception (MAX) | +25.39% |
| 2025 | +18.26% |
| 2024 | +22.62% |
| 2023 | -7.82% |
| 2022 | +22.39% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 28.57% |
| Volatility 3 years | 24.98% |
| Volatility 5 years | 23.71% |
| Return per risk 1 year | 0.94 |
| Return per risk 3 years | 0.59 |
| Return per risk 5 years | 0.70 |
| Maximum drawdown 1 year | -22.54% |
| Maximum drawdown 3 years | -28.91% |
| Maximum drawdown 5 years | -31.24% |
| Maximum drawdown since inception | -57.63% |
Rolling 1 year volatility
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.